Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers

HH Zhou*, L Choi, H Lau, U Bruntsch, EEGE De Vries, G Eckhardt, AT Van Oosterom, J Verweij, H Schran, N Barbet, R Linnartz, R Capdeville

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

26 Citations (Scopus)

Abstract

SAM486A (previously termed CGP 48664), a potent inhibitor of S-adenosylmethionine decarboxylase, is under clinical development for the treatment of advanced refractory malignancies. Hematological toxicity manifested by dose-dependent neutropenia has been observed in phase I studies. Population methods were used to investigate pharmacokinetics (PK) as a prognostic factor for safety end point (hematological toxicity) in patients with advanced cancers. SAM486A plasma concentrations and neutrophil counts were collected from three ascending-dose tolerability and PK studies (study 1: single 5-day continuous intravenous (IV) infusion with doses ranging from 24-700 mg/m(2)/cycle; study 2:10-minute to 3-hour IV infusion once weekly with doses ranging from 16-325 mg/m(2)/week; study 3:1-hour IV infusion once daily for 5 days with doses ranging from 3.6-202.8 mg/m(2)/day). The FK of SAM486A were best estimated by a population linear three-compartment model with NONMEM (version 5) using data from 79 patients in studies 1 through 3. The population pharmacokinetic parameters (SD) were CL = 6.2 (0.4) l/h/m(2), Q(2) = 15.4(1.5) l/h/m(2), Q(3) = 33.6 (5.3) l/h/m(2), V(1) = 9.5 (1.6) l/m(2), V(2) = 672 (52) l/m(2), and V(3) = 39.9 (8.3) l/m(2), and the corresponding intersubject variability was 45.4%, 74.0%, 85.3% 80.1%, 37.0%, and 103%, respectively where CL is total body clearance, Q(2) and Q(3) are intercompartmentaI clearances, and V(1), V(2), and V(3) are the volumes of distribution in central and peripheral compartments, respectively The intrasubject variability was 24.0%. The cumulative AUC before the onset of neutrophil nadir count (AUC) and the duration of exposure over threshold SAM486A concentrations in the range of 0.05 to 0.1 mu M based on Bayesian PK parameter estimates significantly correlated with absolute neutrophil count nadir (<5 x 10(9)/l). AUC showed the best correlation (R(2) = 0.72) with absolute neutrophil count nadir by an inhibitory sigmoid E(max) model and also correlated with percent decrease in neutrophil count from baseline to nadir by a simple E(max) model (R(2) = 0.53). Logistic regression analysis indicated that AUC and the duration of exposure over 0.05 to 0.1 mu M, but not C(max) were strong predictors of grade 4 neutropenia (<0.5 x 10(9)/l). Drug exposure parameters such as AUC derived from population analysis may be used clinically as a useful predictor of drug-induced neutropenia. (C) 2000 the American College of Clinical Pharmacology.

Original languageEnglish
Pages (from-to)275-283
Number of pages9
JournalThe Journal of Clinical Pharmacology
Volume40
Issue number3
Publication statusPublished - Mar-2000

Keywords

  • S-ADENOSYLMETHIONINE DECARBOXYLASE
  • 2'-AMIDINOHYDRAZONE CGP 48664A
  • ANTITUMOR-ACTIVITY
  • ENZYME TARGET
  • PACLITAXEL
  • INHIBITOR
  • GROWTH
  • PHARMACODYNAMICS
  • LEUKEMIA
  • THERAPY

Cite this